{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T09:58:28Z","timestamp":1787997508253,"version":"build-2784847793"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>While adult clinical trials of coronavirus disease 2019 (COVID-19) vaccines have moved quickly into phase 3 clinical trials, clinical trials have not started in children in the United States. The direct COVID-19 impact upon children is greater than that observed for a number of other pathogens for which we now have effective pediatric vaccines. Additionally, the role of children in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission has clearly been underappreciated. Carefully conducted phase 2 clinical trials can adequately address potential COVID-19 vaccine safety concerns. Delaying phase 2 vaccine clinical trials in children will delay our recovery from COVID-19 and unnecessarily prolong its impact upon children\u2019s education, health, and emotional well-being, and equitable access to opportunities for development and social success. Given the potential direct and indirect benefits of pediatric vaccination, implementation of phase 2 clinical trials for COVID-19 vaccines should begin now.<\/jats:p>","DOI":"10.1093\/cid\/ciaa1425","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T15:25:48Z","timestamp":1600269948000},"page":"336-340","source":"Crossref","is-referenced-by-count":77,"title":["Warp Speed for Coronavirus Disease 2019 (COVID-19) Vaccines: Why Are Children Stuck in Neutral?"],"prefix":"10.1093","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-4420","authenticated-orcid":false,"given":"Evan J","family":"Anderson","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA"},{"name":"Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA"},{"name":"Center for Childhood Infections and Vaccines, Children\u2019s Healthcare of Atlanta, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Buddy","family":"Creech","sequence":"additional","affiliation":[{"name":"Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Frenck","sequence":"additional","affiliation":[{"name":"Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, Ohio,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kamidani","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA"},{"name":"Center for Childhood Infections and Vaccines, Children\u2019s Healthcare of Atlanta, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flor M","family":"Munoz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA"},{"name":"Department of Molecular Virology and Microbiology, Baylor College of Medicine \u00a0, Houston, Texas, \u00a0USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Nachman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The State University of New York (SUNY) Stony Brook; Stony Brook, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5393-9511","authenticated-orcid":false,"given":"Paul","family":"Spearman","sequence":"additional","affiliation":[{"name":"Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, Ohio,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,18]]},"reference":[{"key":"2021102307041861200_CIT0001","article-title":"SARS-CoV-2 mRNA vaccine development enabled by prototy","author":"Corbett","year":"2020","journal-title":"bioRxiv"},{"key":"2021102307041861200_CIT0002","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2022483","article-title":"A SARS-CoV-2 mRNA vaccine\u2014preliminary report [reply]","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"key":"2021102307041861200_CIT0003","article-title":"Phase 1\/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: interim report","author":"Mulligan","year":"2020","journal-title":"medRxiv"},{"key":"2021102307041861200_CIT0004","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"2021102307041861200_CIT0005","article-title":"RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study","author":"Walsh","year":"2020","journal-title":"medRxiv"},{"key":"2021102307041861200_CIT0006","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1\u20132 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","author":"Keech","year":"2020","journal-title":"N Engl J Med"},{"key":"2021102307041861200_CIT0007","author":"Centers for Disease Control and Prevention"},{"key":"2021102307041861200_CIT0008","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.15585\/mmwr.mm6932e3","article-title":"Hospitalization rates and characteristics of children aged &lt;18 years hospitalized with laboratory-confirmed COVID-19\u2014COVID-NET, 14 states, March 1-July 25, 2020","volume":"69","author":"Kim","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021102307041861200_CIT0009","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1056\/NEJMoa2021680","article-title":"Multisystem inflammatory syndrome in U.S. children and adolescents","volume":"383","author":"Feldstein","year":"2020","journal-title":"N Engl J Med"},{"key":"2021102307041861200_CIT0010","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-009951","article-title":"Racial\/ethnic and socioeconomic disparities of SARS-CoV-2 infection among children","author":"Goyal","year":"2020","journal-title":"Pediatrics"},{"key":"2021102307041861200_CIT0011","author":"Centers for Disease Control and Prevention"},{"key":"2021102307041861200_CIT0012","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1097\/00006454-200210000-00009","article-title":"Hospitalizations for varicella in the United States, 1988 to 1999","volume":"21","author":"Galil","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"2021102307041861200_CIT0013","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1086\/315714","article-title":"Varicella mortality: trends before vaccine licensure in the United States, 1970\u20131994","volume":"182","author":"Meyer","year":"2000","journal-title":"J Infect Dis"},{"key":"2021102307041861200_CIT0014","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1001\/jama.298.18.2155","article-title":"Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States","volume":"298","author":"Roush","year":"2007","journal-title":"JAMA"},{"key":"2021102307041861200_CIT0015","first-page":"1","article-title":"Surveillance for acute viral hepatitis\u2014United States, 2005","volume":"56","author":"Wasley","year":"2007","journal-title":"MMWR Surveill Summ"},{"key":"2021102307041861200_CIT0016","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1086\/586899","article-title":"Declining hepatitis A mortality in the United States during the era of hepatitis A vaccination","volume":"197","author":"Vogt","year":"2008","journal-title":"J Infect Dis"},{"key":"2021102307041861200_CIT0017","first-page":"1","article-title":"Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"55","author":"Parashar","year":"2006","journal-title":"MMWR Recomm Rep"},{"key":"2021102307041861200_CIT0018","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/01.inf.0000215234.91997.21","article-title":"Hospitalizations associated with rotavirus gastroenteritis in the United States, 1993\u20132002","volume":"25","author":"Charles","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"2021102307041861200_CIT0019","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1097\/INF.0b013e318220fe20","article-title":"Rotavirus-coded deaths in children, United States, 1999\u20132007","volume":"30","author":"Desai","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"2021102307041861200_CIT0020","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1097\/INF.0b013e3182254d19","article-title":"Baseline estimates of diarrhea-associated mortality among United States children before rotavirus vaccine introduction","volume":"30","author":"Esposito","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"2021102307041861200_CIT0021","author":"Centers for Disease Control and Prevention"},{"key":"2021102307041861200_CIT0022","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/cid\/ciy142","article-title":"Protecting the community through child vaccination","volume":"67","author":"Anderson","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2021102307041861200_CIT0023","article-title":"The importance of advancing SARS-CoV-2 vaccines in children","author":"Kao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021102307041861200_CIT0024","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/infdis\/jir492","article-title":"Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States","volume":"204","author":"Lopman","year":"2011","journal-title":"J Infect Dis"},{"key":"2021102307041861200_CIT0025","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1473-3099(14)71081-3","article-title":"Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance","volume":"15","author":"Moore","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2021102307041861200_CIT0026","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa022823","article-title":"Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine","volume":"348","author":"Whitney","year":"2003","journal-title":"N Engl J Med"},{"key":"2021102307041861200_CIT0027","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.vaccine.2004.09.025","article-title":"Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children","volume":"23","author":"Piedra","year":"2005","journal-title":"Vaccine"},{"key":"2021102307041861200_CIT0028","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJM200103223441204","article-title":"The Japanese experience with vaccinating schoolchildren against influenza","volume":"344","author":"Reichert","year":"2001","journal-title":"N Engl J Med"},{"key":"2021102307041861200_CIT0029","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.2010.250","article-title":"Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial","volume":"303","author":"Loeb","year":"2010","journal-title":"JAMA"},{"key":"2021102307041861200_CIT0030","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.15585\/mmwr.mm6846a5","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged &gt;\/=65 years: updated Recommendations of the Advisory Committee on Immunization Practices","volume":"68","author":"Matanock","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021102307041861200_CIT0031","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates","author":"Corbett","year":"2020","journal-title":"N Engl J Med"},{"key":"2021102307041861200_CIT0032","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S1473-3099(20)30287-5","article-title":"Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study","volume":"20","author":"Bi","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2021102307041861200_CIT0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2020.08.037","article-title":"Pediatric SARS-CoV-2: clinical presentation, infectivity, and immune responses","author":"Yonker","year":"2020","journal-title":"J Pediatr"},{"key":"2021102307041861200_CIT0034","doi-asserted-by":"crossref","DOI":"10.1001\/jamapediatrics.2020.3651","article-title":"Age-related differences in nasopharyngeal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) levels in patients with mild to moderate coronavirus disease 2019 (COVID-19)","author":"Heald-Sargent","year":"2020","journal-title":"JAMA Pediatr"},{"key":"2021102307041861200_CIT0035","article-title":"Contact tracing during coronavirus disease outbreak, South Korea, 2020","volume":"26:2465\u20138. PMID: 32673193","author":"Park","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"2021102307041861200_CIT0036","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.15585\/mmwr.mm6931e1","article-title":"SARS-CoV-2 transmission and infection among attendees of an overnight camp\u2014Georgia, June 2020","volume":"69","author":"Szablewski","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021102307041861200_CIT0037","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1001\/jama.2020.14348","article-title":"Association between statewide school closure and COVID-19 incidence and mortality in the US","volume":"324","author":"Auger","year":"2020","journal-title":"JAMA"},{"key":"2021102307041861200_CIT0038","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"2021102307041861200_CIT0039","article-title":"First-in-human trial of a SARS CoV 2 recombinant spike protein nanoparticle vaccine","author":"Keech","year":"2020","journal-title":"medRxiv"},{"key":"2021102307041861200_CIT0040","doi-asserted-by":"crossref","first-page":"e687","DOI":"10.1542\/peds.2007-1578","article-title":"Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children","volume":"121","author":"France","year":"2008","journal-title":"Pediatrics"},{"key":"2021102307041861200_CIT0041","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-0320","article-title":"Febrile seizure risk after vaccination in children 6 to 23 mon","volume":"138","author":"Duffy","year":"2016","journal-title":"Pediatrics"},{"key":"2021102307041861200_CIT0042","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJM200102223440804","article-title":"Intussusception among infants given an oral rotavirus vaccine","volume":"344","author":"Murphy","year":"2001","journal-title":"N Engl J Med"},{"key":"2021102307041861200_CIT0043","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jpeds.2020.06.048","article-title":"Anticipating severe acute respiratory syndrome coronavirus 2 vaccine testing, licensure, and recommendations for use","volume":"224","author":"Edwards","year":"2020","journal-title":"J Pediatr"},{"key":"2021102307041861200_CIT0044","doi-asserted-by":"crossref","first-page":"445","DOI":"10.7326\/M20-2726","article-title":"Postmarketing safety of vaccines approved by the U.S. Food and Drug Administration: a cohort study","volume":"173","author":"Tau","year":"2020","journal-title":"Ann Intern Med"},{"key":"2021102307041861200_CIT0045","author":"Food and Drug Administration"},{"key":"2021102307041861200_CIT0046","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1126\/science.abb8923","article-title":"Rapid COVID-19 vaccine development","volume":"368","author":"Graham","year":"2020","journal-title":"Science"},{"key":"2021102307041861200_CIT0047","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","article-title":"Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus","volume":"182","author":"Korber","year":"2020","journal-title":"Cell"},{"key":"2021102307041861200_CIT0048","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"2021102307041861200_CIT0049","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-018242","article-title":"Quantitative SARS-CoV-2 serology in children with multisystem inflammatory syndrome (MIS-C)","author":"Rostad","year":"2020","journal-title":"Pediatrics"},{"key":"2021102307041861200_CIT0050","doi-asserted-by":"crossref","first-page":"m1443","DOI":"10.1136\/bmj.m1443","article-title":"Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study","volume":"369","author":"Zheng","year":"2020","journal-title":"BMJ"},{"key":"2021102307041861200_CIT0051","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.abc6284","article-title":"DNA vaccine protection against SARS-CoV-2 in rhesus macaques","volume":"369","author":"Yu","year":"2020","journal-title":"Science"},{"key":"2021102307041861200_CIT0052","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2607-z","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques","author":"Mercado","year":"2020","journal-title":"Nature"},{"key":"2021102307041861200_CIT0053","author":"US Department of Health and Human Services"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa1425\/37549926\/ciaa1425.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/2\/336\/40828474\/ciaa1425.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/2\/336\/40828474\/ciaa1425.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T03:04:49Z","timestamp":1634958289000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/2\/336\/5908283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,18]]},"references-count":53,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,9,18]]},"published-print":{"date-parts":[[2021,7,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa1425","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,15]]},"published":{"date-parts":[[2020,9,18]]}}}